COMPANY

Circle Pharma

HQ: South San Francisco, CA source · circlepharma.com ↗

Keywords: oncology cancer Lung Cancer Triple Negative Breast Cancer Breast Neoplasms Neuroendocrine Tumors Neuroendocrine Carcinoma RB1 Gene Mutation CID-078 Monotherapy

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series E · $92.5M · announced Sep 16, 2026 Company release ↗
Source quote
- Sep 16, 2026 · Company release ↗
  “Circle Pharma Announces $92.5 Million Series E Financing to Advance First-in-class Cyclin D1 Program into Clinical Development”

Raises announced in these releases: $92.5M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 16, 2026 Raise Series E · $92.5M source ↗
Aug 14, 2024 Trial start Phase 1: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies source ↗

Upcoming milestones

Jan 14, 2027 (ESTIMATED) · Phase 1 · Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies · NCT06577987

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06577987	Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies	Phase 1	Active, not recruiting	Aug 14, 2024	Jan 14, 2027 (estimated)